116 related articles for article (PubMed ID: 26927816)
1. Pharmacodynamics of alacepril in healthy cats.
Sugimoto K; Fujii Y; Takubo I; Shiga T; Sunahara H; Aoki T; Orito K
J Feline Med Surg; 2017 Jun; 19(6):706-709. PubMed ID: 26927816
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
3. Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet.
Miyazaki M; Takai S
Hypertens Res; 1999 Mar; 22(1):49-54. PubMed ID: 10221351
[TBL] [Abstract][Full Text] [Related]
4. A paradoxical increase in circulating ACE (angiotensin converting enzyme) activity after long-term administration of alacepril (ACE inhibitor).
Nishida S; Matsuki M; Sumitomo S; Kawai Y; Yoneda M
Horm Metab Res; 1997 Mar; 29(3):153-4. PubMed ID: 9137988
[No Abstract] [Full Text] [Related]
5. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.
Nonoguchi H; Kiyama S; Kitamura K; Naruse M; Tomita M; Tazoe N; Tajiri M; Nakayama Y; Kohda Y; Inoue T; Tomita K
Hypertens Res; 2008 Jan; 31(1):29-36. PubMed ID: 18360015
[TBL] [Abstract][Full Text] [Related]
6. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
Uechi M; Imamoto S; Ishikawa Y
J Vet Med Sci; 2002 Apr; 64(4):385-7. PubMed ID: 12014588
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
Sakatani A; Miyagawa Y; Takemura N
J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
[TBL] [Abstract][Full Text] [Related]
9. ACE activity during the hypotension produced by standardized aqueous extract of Cecropia glaziovii Sneth: a comparative study to captopril effects in rats.
Ninahuaman MF; Souccar C; Lapa AJ; Lima-Landman MT
Phytomedicine; 2007 May; 14(5):321-7. PubMed ID: 17433647
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
[TBL] [Abstract][Full Text] [Related]
11. Comparison of acute cardiovascular effects of cadmium and captopril in relation to oxidant and angiotensin converting enzyme activity in rats.
Puri VN; Saha S
Drug Chem Toxicol; 2003 Aug; 26(3):213-8. PubMed ID: 12953661
[TBL] [Abstract][Full Text] [Related]
12. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
[TBL] [Abstract][Full Text] [Related]
13. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Kinugawa T; Kato M; Mori M; Endo A; Kato T; Hamada T; Noguchi N; Omodani H; Osaki S; Ogino K; Miyakoda H; Hisatome I; Shigemasa C
Eur J Clin Pharmacol; 1998 May; 54(3):209-14. PubMed ID: 9681661
[TBL] [Abstract][Full Text] [Related]
15. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
Ideishi M; Sasaguri M; Ikeda M; Arakawa K
Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment.
Murohara T; Tayama S; Tabuchi T; Sumida H; Honda T; Hayasaki K; Yasue H
Am J Cardiol; 1996 Jun; 77(14):1159-63. PubMed ID: 8651088
[TBL] [Abstract][Full Text] [Related]
17. Serum angiotensin converting enzyme activity and response to angiotensin I in horses.
Tillman LG; Moore JN
Equine Vet J Suppl; 1989 Jun; (7):80-3. PubMed ID: 9118114
[TBL] [Abstract][Full Text] [Related]
18. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
Yoshimura M; Yasue H; Tanaka H; Kikuta K; Sumida H; Kato H; Jougasaki M; Nakao K
Br Heart J; 1994 Dec; 72(6):528-33. PubMed ID: 7857734
[TBL] [Abstract][Full Text] [Related]
19. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
[TBL] [Abstract][Full Text] [Related]
20. Free radical scavenging properties of alacepril metabolites and lisinopril.
Noda Y; Mori A; Packer L
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):125-36. PubMed ID: 9226747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
